The UK authorities have approved Oxford/AstraZeneca’s adenovirus vector vaccine for distribution there. Of special interest is the intent to give as many people as possible a first shot, without holding back supplies for the second round. This is simultaneously the correct decision for them to make and also very bad news.
Data on Johnson & Johnson’s one-dose clinical trial of this adenovirus vector candidate should be coming very soon indeed. It's going to be of great interest, given the results from the Oxford/AstraZeneca effort and given the deliberate one-dose protocol.
Novavax's trial should be the next one we hear about after Johnson & Johnson reports, and a lot of people are waiting to see how this recombinant protein candidate works out. These will be results from a trial in the UK - a US Phase 3 just launched this week.
Market Data 
Markets 
AI
